Metraipolis › archive › dc_215b29b9501b

The cost effectiveness of toripalimab plus bevacizumab versus sorafenib for the first-line treatment of advanced hepatocellular carcinoma in China — Europe PMC PMID:41919240

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41919240
DOI
10.3389/fphar.2026.1726444
License (as archived)
solo-consultazione
Archived
2026-11-04T09:24:49.826Z
SHA-256 of the archived text
943e4eef83fc5efb12a8be2d02b6e25d910d0952b1b1a5c446033700c8423153
Stable URL of this page
https://metraipolis.com/documento/dc_215b29b9501b

How to cite

The cost effectiveness of toripalimab plus bevacizumab versus sorafenib for the first-line treatment of advanced hepatocellular carcinoma in China — Europe PMC PMID:41919240 — Europe PMC (en), https://europepmc.org/article/MED/41919240 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_215b29b9501b (Metraipolis archive dc_215b29b9501b, sha256 943e4eef83fc5efb12a8be2d02b6e25d910d0952b1b1a5c446033700c8423153)
BibTeX
@misc{dc215b29b9501b,
  title = {The cost effectiveness of toripalimab plus bevacizumab versus sorafenib for the first-line treatment of advanced hepatocellular carcinoma in China — Europe PMC PMID:41919240},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41919240},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_215b29b9501b; sha256 943e4eef83fc5efb12a8be2d02b6e25d910d0952b1b1a5c446033700c8423153},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41919240. Agents can read the archived copy with the MCP tool read_document.